MAP2 and stroke disorder: On the other hand, despite its acute sensitivity to ischemic insults [36, 40, 64] and its ischemia-associated degradation by the Ca2+-dependent proteases calpain and caspase [38, 39], the value of MAP2 as a potential biomarker in the clinical setting of stroke has so far been largely neglected.